Efektivitas Terapi Kombinasi Metformin dan Glimepiride pada Pasien Diabetes Mellitus Tipe 2 : Tinjauan Literatur

Desak Nandini Prameswari Pagedongan; Ketut Widyani Astuti

doi:10.62027/praba.v3i3.493

Authors

Desak Nandini Prameswari Pagedongan Universitas Udayana
Ketut Widyani Astuti Universitas Udayana

DOI:

https://doi.org/10.62027/praba.v3i3.493

Keywords:

Fixed Dose Combination, Glimepiride, Metformin, Patient, Type 2 Diabetes Mellitus

Abstract

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia due to insulin resistance, decreased insulin secretion, or a combination of both. The burden of this disease continues to increase globally, making effective, safe, and affordable management an urgent need. One widely used therapeutic strategy is the fixed-dose combination (FDC) of metformin and glimepiride. This combination is considered beneficial because the two drugs complement each other in their mechanisms of action: metformin reduces hepatic glucose production and increases insulin sensitivity, while glimepiride stimulates insulin secretion from pancreatic β-cells. Furthermore, the use of FDC can simplify the treatment regimen, thereby improving patient adherence to long-term therapy. Article searches were conducted through Google Scholar and PubMed with the keywords "((Metformin) AND (Glimepiride)) AND (T2DM) AND (Fixed Dose Combination)", covering publications from 2020–2025 in both English and Indonesian. Of the total articles found, 15 studies met the inclusion criteria for further analysis. The review results showed that the use of metformin–glimepiride FDC was able to reduce HbA1c levels between 0.33% and 2.45%, reducing fasting plasma glucose (FPG) levels by 32–65 mg/dL, and postprandial plasma glucose (PPG) by 38–103 mg/dL. Most studies reported achieving glycemic targets as recommended by the American Diabetes Association (ADA). The most commonly reported side effects were mild hypoglycemia with an incidence of 4.8%–34.5% and gastrointestinal disturbances, but the overall safety profile of this combination was still acceptable. In terms of cost, FDC was considered more economical than the use of separate single drugs. Thus, metformin–glimepiride FDC was proven to be effective, relatively safe, and affordable in glycemic control in T2DM patients, especially in countries with limited resources. These findings support its use as a primary choice in clinical practice.

References

Amin, S., Saraswati, E., Ilhami, D. A. D., Muliadi, P., Anggraeni, Y. D., & Pratama, A. (2025). Mekanisme kerja obat anti diabetes golongan biguanid dan sulfonilurea tinjauan kimia medisinal. Jurnal Ners, 9(2), 2981–2986. https://doi.org/10.31004/jn.v9i2.44627

Apriliany, F., Cholisah, E., & Erlianti, K. (2022). Efek pemberian metformin dan metformin + glimepiride terhadap kadar HbA1c pada pasien diabetes mellitus tipe 2. Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 12(2), 97. https://doi.org/10.22146/jmpf.72192

Gopal, K., Singh, S. K., Bhardwaj, V. K., Jain, P., Sinha, P., Jain, A., Rastogi, A., Sondhi, S. P., Singhal, T., Modi, A. L., Mahule, A., Prasad, A., & Pednekar, A. (2025). Usage of glimepiride and metformin combination in young adults (below 30 years of age) with type 2 diabetes mellitus in Indian settings. Global Journal for Research Analysis, 14(2), 39–44. https://doi.org/10.36106/gjra

Hafizi, A., Hasbie, N. F., Febriyani, A., & Kurniati, M. (2025). Hubungan antara usia, jenis kelamin dan indeks massa tubuh dengan kejadian diabetes mellitus tipe 2 di Rumah Sakit Pertamina Bintang Amin Husada. Jurnal Medika Malahayati, 8(4), 900–907. https://doi.org/10.33024/jmm.v8i4.17069

Indarto, I., Widiyanto, A., & Atmojo, J. T. (2023). Efektivitas metformin dalam penurunan kadar glukosa pada pasien diabetes mellitus tipe-2: Meta-analisis. Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal, 13(2), 621–630. https://doi.org/10.32583/pskm.v13i2.852

Indriyani, Ludiana, & Dewi, T. K. (2023). Penerapan senam kaki diabetes melitus terhadap kadar glukosa darah pada penderita diabetes melitus di Puskesmas Yosomulyo. Jurnal Cendikia Muda, 3(2), 252–259. https://jurnal.akperdharmawacana.ac.id/index.php/JWC/article/view/466

Islam, K., Islam, R., Nguyen, I., Malik, H., Pirzadah, H., Shrestha, B., Lentz, I. B., Shekoohi, S., & Kaye, A. D. (2025). Diabetes mellitus and associated vascular disease: Pathogenesis, complications, and evolving treatments. Advances in Therapy, 42(6), 2659–2678. https://doi.org/10.1007/s12325-025-03185-9

Karmur, M. A., Talwalkar, P. G., Supe, P. D., Patange, S. A., Bhojane, S., Panchani, R., Kothary, S., Shah, S. D., Chandratreya, S., Prasad, A., & Talathi, M. (2022). Usage of glimepiride/metformin fixed-dose combination with insulin in management of type 2 diabetes mellitus: An Indian experience. Asian Journal of Diabetology, 23(2), 20–26.

Kumar Reddy, S., Kumar, S. M., D, S. L., Damodar, R. H., & Ahamed Shaik, R. (2021). Comparative efficacy and safety of glimepiride–metformin versus glibenclamide–metformin combination in type 2 diabetics uncontrolled with metformin alone. International Journal of Health and Clinical Research, 4(13), 61–65. http://www.ijhcr.com

Kumar, S. (2021). Comparison of safety and efficacy of glimepiride–metformin and vildagliptin–metformin treatment in newly diagnosed type 2 diabetic patients. Indian Journal of Endocrinology and Metabolism, 25(4), 326–331. https://doi.org/10.4103/ijem.ijem_276_21

Lee, D. S. U., & Lee, H. (2022). Adherence and persistence rates of major antidiabetic medications: A review. Diabetology and Metabolic Syndrome, 14(1), 1–23. https://doi.org/10.1186/s13098-022-00785-1

Lim, S., Sohn, M., Florez, J. C., Nauck, M. A., & Ahn, J. (2023). Effects of initial combinations of gemigliptin plus metformin compared with glimepiride plus metformin on gut microbiota and glucose regulation in obese patients with type 2 diabetes: The INTESTINE study. Nutrients, 15(1), 1–14. https://doi.org/10.3390/nu15010248

Mayabhate, M., Kapure, N., & Sharma, A. (2025). GLIMPSE study: Exploring the effectiveness of glimepiride and metformin combination therapy in newly diagnosed type 2 diabetes in India. International Journal of Advances in Medicine, 12(4), 387–394. https://doi.org/10.18203/2349-3933.ijam20251937

Murtiningsih, M. K., Pandelaki, K., & Sedli, B. P. (2021). Gaya hidup sebagai faktor risiko diabetes melitus tipe 2. E-CliniC, 9(2), 328. https://doi.org/10.35790/ecl.v9i2.32852

Nurgajayanti, C., Susilawati, T. N., & Wiboworini, B. (2024). The duration of diabetes mellitus affects long-term glycemic control measured through HbA1c in patients with type 2 diabetes mellitus. Media Penelitian dan Pengembangan Kesehatan, 34(3), 563–570. https://doi.org/10.34011/jmp2k.v34i3.2085

Prasanna Kumar, K., Seshadri, K., Aravind, S., Deb, P., Modi, K., Gopal, R. A., G, V. K., Moses, C. A., Abhyankar, M., & Revenkar, S. (2021). Real-world observational study of glimepiride and metformin fixed-dose combination along with insulin in the management of type 2 diabetes mellitus: Indian experience. Cureus, 13(1), e13020. https://doi.org/10.7759/cureus.13020

Ram Pratap Sah, Paudel, P., Thapa, S., Shrestha, M. R., Shrestha, M., Poudyal, S., & Mahule, A. (2025). Assessing the efficacy and safety of combined glimepiride and metformin therapy in type 2 diabetes mellitus management. World Journal of Advanced Research and Reviews, 25(2), 1984–1992. https://doi.org/10.30574/wjarr.2025.25.2.0445

Rasheed, R. A., Venkatraman, G., Vijayalakshmi, S., Raja, T. A. R., Senthil, G., & Renugadevi, P. (2024). Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients. Indian Journal of Pharmacology, 56(5), 317–321. https://doi.org/10.4103/ijp.ijp_107_24

Sahay, R. K., Mittal, V., Gopal, G. R., Kota, S., Goyal, G., Abhyankar, M., & Revenkar, S. (2020). Glimepiride and metformin combinations in diabetes comorbidities and complications: Real-world evidence. Cureus, 12(9), e10700. https://doi.org/10.7759/cureus.10700

Sheikh, S., Nagendra, L., Sinha, B., Bansal, B., Dey, A., Kumar, S., Ghatnatti, V., Mahule, A., Pednekar, A., & Prasad, A. (2024). Usage of glimepiride and metformin combination in type 2 diabetes patients with established complications in Indian settings. International Journal of Diabetes and Technology, 3(2), 74–79. https://doi.org/10.4103/ijdt.ijdt_23_24

Sinha, B., Kant, S., Bandyopadhyay, S., Mukherjee, S., Sarkar, D., Singh, K. P., Chaudhury, T., Kumar, S., Ahmed, R., Abhyankar, M., Prasad, A., & Talathi, M. (2022). Clinical utility of glimepiride and metformin fixed-dose combination in obese/overweight patients with type 2 diabetes mellitus in Indian settings. Chronicle of Diabetes Research and Practice, 1(2), 58–68. https://doi.org/10.4103/cdrp.cdrp_5_22

Udayani, N. N. W., Wardani, I. G. A. A. K., & Nida, I. D. A. A. Y. (2022). Side effects evaluation of the use of metformin and glimepiride combination in type 2 diabetes mellitus outpatients. Jurnal Ilmiah Medicamento, 8(2), 99–103. https://doi.org/10.36733/medicamento.v8i2.3164

Wikannanda, I. A. A. D., Sari, N. L. P. E. K., & Aryastuti, A. A. S. A. (2023). Gambaran penggunaan terapi kombinasi oral metformin–sulfonilurea pada pasien DM tipe 2 di Denpasar. Aesculapius Medical Journal, 3(2), 224–232. https://doi.org/10.22225/amj.3.2.2023.224-232